Xtandi phase-3 shows statsig-superior MFS* both as an addend to Lupron (compared to Lupron alone) and as monotherapy compared to Lupron in non-metastatic HSPC patients at high-risk for disease recurrence:
The (secondary endpoint) OS data are not yet mature, but are trending positively for Xtandi + Lupron vs Lupron alone. The full dataset will be presented at an unspecified medical conference.
PFE booked $1.2B in Xtandi-alliance revenue in 2022 pursuant to its worldwide collaboration with Astellas that splits US profits 50/50 and pays PFE royalties on ex-US sales. Xtandi goes off-patent in the US in 2027.
Market Data 
Markets 
